Jianxing He

Research interests

Publications

• Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

  Cancer Cell · 2022 · https://doi.org/10.1016/j.ccell.2022.02.007

• Neoadjuvant Osimertinib With/Without Chemotherapy Versus Chemotherapy Alone for EGFR -Mutated Resectable Non-Small-Cell Lung Cancer: NeoADAURA

  Future Oncology · 2021 · https://doi.org/10.2217/fon-2021-0549

• The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis

  EClinicalMedicine · 2021 · https://doi.org/10.1016/j.eclinm.2021.101134

• Clinical characteristics of 2019 novel coronavirus infection in China

  medRxiv · 2020 · https://doi.org/10.1101/2020.02.06.20020974

• Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis

  medRxiv · 2020 · https://doi.org/10.1101/2020.02.25.20027664

• Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China

  CHEST Journal · 2020 · https://doi.org/10.1016/j.chest.2020.04.010

• Clinical Characteristics of Coronavirus Disease 2019 in China

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2002032

• Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30096-6

• Early triage of critically ill COVID-19 patients using deep learning

  Nature Communications · 2020 · https://doi.org/10.1038/s41467-020-17280-8

• Modified SEIR and AI prediction of the epidemics trend of COVID-19 in China under public health interventions

  Journal of Thoracic Disease · 2020 · https://doi.org/10.21037/jtd.2020.02.64

• Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography

  Cell · 2020 · https://doi.org/10.1016/j.cell.2020.04.045

• Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19

  JAMA Internal Medicine · 2020 · https://doi.org/10.1001/jamainternmed.2020.2033

• Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China

  Journal of Allergy and Clinical Immunology · 2020 · https://doi.org/10.1016/j.jaci.2020.05.003

• Pyrotinib in HER2 -Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.20.00297

• Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(18)32409-7

• Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA)

  Theranostics · 2019 · https://doi.org/10.7150/thno.28119

• Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

  The Lancet Respiratory Medicine · 2019 · https://doi.org/10.1016/s2213-2600(19)30053-0

• Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

  JAMA Oncology · 2018 · https://doi.org/10.1001/jamaoncol.2018.3039

• The practical implementation of artificial intelligence technologies in medicine

  Nature Medicine · 2018 · https://doi.org/10.1038/s41591-018-0307-0

• Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non–Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2016.67.5140

• Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)00099-1

• Choice of Surgical Procedure for Patients With Non–Small-Cell Lung Cancer ≤ 1 cm or > 1 to 2 cm Among Lobectomy, Segmentectomy, and Wedge Resection: A Population-Based Study

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2015.64.6729

• BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.59.4424

• Development and Validation of a Nomogram for Predicting Survival in Patients With Resected Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.56.6661

• Video-assisted thoracoscopic surgery lobectomy at 20 years: a consensus statement

  European Journal of Cardio-Thoracic Surgery · 2013 · https://doi.org/10.1093/ejcts/ezt463

• A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies

  The Lancet · 2012 · https://doi.org/10.1016/s0140-6736(11)61941-7

Current projects

No projects listed.